|
Nabi Biopharmacetuicals was a drug development company in Rockville, Maryland. Its principle product was NicVAX (also known as 3′AmNic-rEPA), a nicotine conjugate vaccine intended to reduce physical addiction to nicotine. The drug was developed with help from the U.S. National Institute of Drug Abuse, and showed promise in early studies, however, two successive phase III trials of the drug in 2009 and 2011 failed.〔(【引用サイトリンク】 title=Nabi Biopharmaceuticals Initiates Pivotal Phase III Study for NicVAX as an Aid to Smoking Cessation and Long-term Abstinence )〕〔()〕 On Thursday, November 8, 2012 the business combination of Nabi Biopharmaceuticals and Biota Holdings Limited became effective to create Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) ==External links== (Biota Pharmaceuticals, Inc. ) ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Nabi Biopharmaceuticals」の詳細全文を読む スポンサード リンク
|